Acylated Ghrelin Shields Rat Hearts from Chemo-Induced Damage

The chemotherapy drug doxorubicin is highly effective against various cancers, but its use is severely limited by cardiotoxicity (heart damage), which can lead to heart failure. A primary mechanism of this damage is apoptosis (programmed cell death), specifically initiated through the Fas/FasL pathway. Developing strategies to protect the heart from doxorubicin-induced cardiotoxicity is critical for improving cancer treatment safety and patient long-term health.

The study found that Acylated Ghrelin treatment significantly counteracted the damaging effects of doxorubicin on rat hearts. It was observed to reduce markers associated with Fas/FasL apoptosis, indicating a substantial decrease in programmed cell death in cardiac cells. This protective effect was mediated through the activation of both PKA and Akt signaling pathways, which are critical for cell survival and growth. Acylated Ghrelin protected heart cells by stimulating SERCA2a (Sarco/endoplasmic reticulum Ca2+-ATPase 2a) activity, a crucial protein for calcium handling in heart muscle, leading to improved cellular function and resilience. These activations led to improved cardiac function and a notable reduction in cell death in the treated animals compared to controls. While the study demonstrated a clear protective effect, specific quantitative data (e.g., percentage reduction, fold-change, p-values) were not detailed in the provided record.